Adial Pharmaceuticals Q3 2023 Earnings Report $1.07 +0.02 (+1.90%) (As of 12/20/2024 05:31 PM ET) Earnings HistoryForecast Adial Pharmaceuticals EPS ResultsActual EPS-$1.14Consensus EPS -$1.14Beat/MissMet ExpectationsOne Year Ago EPSN/AAdial Pharmaceuticals Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AAdial Pharmaceuticals Announcement DetailsQuarterQ3 2023Date11/14/2023TimeN/AConference Call ResourcesADIL Earnings History Trump’s Sending THIS Crypto Higher on Purpose (Ad)Discover the coin set to explode before 2025! Trump could trigger THIS crypto coin… YES, I WANT THE #1 CRYPTO NOW Adial Pharmaceuticals Earnings HeadlinesAdial Pharmaceuticals files to sell 5.0M shares of common stock for holdersDecember 21 at 12:14 AM | markets.businessinsider.comAdial Pharmaceuticals Enters Purchase Agreement with Alumni Capital; Allows Sale of Up to $10 Million in Common StockDecember 20 at 4:13 AM | americanbankingnews.comTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… December 22, 2024 | Crypto 101 Media (Ad)Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Short Interest UpdateDecember 12, 2024 | americanbankingnews.comAdial granted U.S. patent for treatment of alcohol, drug dependenceDecember 3, 2024 | markets.businessinsider.comEXCLUSIVE: Adial Pharmaceuticals' Lead Drug Secures Key US Patent For Alcohol Dependence Based on Expanded Genotype CombinationsDecember 3, 2024 | finance.yahoo.comSee More Adial Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adial Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adial Pharmaceuticals and other key companies, straight to your email. Email Address About Adial PharmaceuticalsAdial Pharmaceuticals (NASDAQ:ADIL), a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.View Adial Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles History Hints at a Rebound for Toll Brothers After EarningsAlibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of Earnings Upcoming Earnings Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
